We recently reported preliminary safety and immunogenicity data from a phase 1/2 trial of the ChAdOx1 nCoV-19 vaccine (NCT04400838)given as either a one- or two-dose regimen. The vaccine was tolerated, with induction of neutralizing antibodies and antigen-specific T cells against the SARS-CoV...
Although previous studies have found an association between antibody-binding titers and neutralization with protection across phase 3 COVID-19 vaccine trials15,48, WT S IgG titers and neutralization were not different across vaccinees who did or did not develop beta-variant COVID-19 after ChAdOX1 ...
参考资料: [1] Oxford University/AstraZeneca vaccine authorised by UK medicines regulator. Retrieved December 30, 2020, from网页链接 [2] AZD1222 Oxford Phase III trials interim analysis results published in The Lancet. Retrieved December 30, 2020, from网页链接 [3] AstraZeneca’s COVID-19 vaccine...
AZD1222 development expanded into a Phase III clinical trial in the US to assess its safety, efficacy and immunogenicity. The US trial, called D8110C00001, is funded by the Biomedical Advanced Development Authority (BARDA), part of the office of the Assi...
1. Clinicaltrials.gov. A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19. [Onli...
Methods: SARS-CoV-2 and HCoV cross-immunity was evaluated in adult participants enrolled in a US sub-study in the phase III, randomized controlled trial (NCT04516746) of AZD1222 (ChAdOx1 nCoV-19) primary-series vaccination for one-year. Anti-HCoV spike-binding antibo...
author correction t ce11 and antibody responses induced by a sing1e dose of chadox1 ncov 19 azd1222 vabetaine in a phase 1 2 c1inica1 tria1In the version of this article initially published, the following names were missing from the author list for the Oxford COVID Vaccine Trial Group:...
R. et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N. Engl. J. Med. 385, 2348–2360 (2021). Article CAS Google Scholar Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis...
19. In a phase II study of ChAdOx1 nCoV-19 in South Africa, in 2000 adults with a median age of 31 years, vaccine efficacy against mild to moderate disease was reduced when the virus recovered after infection was B.1.351 (19 cases in the vaccinated group and 20 in the placebo group)...
author correction t ce11 and antibody responses induced by a sing1e dose of chadox1 ncov 19 azd1222 vabetaine in a phase 1 2 c1inica1 tria1In the version of this article initially published, the following names were missing from the author list for the Oxford COVID Vaccine Trial Group:...